Objetivo
1.3 million – this is the sad number of Europeans dying each year by cancer. JenLab, high-tech company from Germany, has therefore developed an innovative novel diagnostic medical device (TRL 7) based on femtosecond laser radiation for immediate, non-invasive early diagnosis of cancer, particularly skin cancer, within seconds and with ultra-high resolution depicting even subcellular level. This is also true for early detection of ophthalmic diseases which constitute a major burden for Europe’s society –knowing that one European in every 30 is expected to experience sight loss. In addition to intratissue cell imaging, JenLab’s technology is able to measure metabolic processes giving information about diseases even before they become visible – increasing therapy success by early detection and continuous monitoring. Moreover, the technology is applicable for imaging each tissue without labelling but using endogenous biomarkers.
Outcome of the business innovation project is an miniaturised, certified and by clinical study validated ultracompact, flexible, fast multiphoton tomograph for dermatologists and ophthalmologists, representing an European market potential of EUR 11.4 bn.
Particularly by its quick and reliable (using 4 different modes of diagnostic) way of diagnosis it meets user needs while simultaneously reducing Europe’s continuously growing health care costs. The business project is in line with JenLab’s philosophy of saving lifes and of facilitate healing as well as it is in line with JenLab’s strategy of developing and producing novel solutions for early diagnosis of life threatening and/or serious diseases.
Ámbito científico
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- medical and health sciencesclinical medicineoncologyskin cancermelanoma
- medical and health sciencesclinical medicineendocrinologydiabetes
- medical and health sciencesclinical medicineophthalmology
- medical and health sciencesclinical medicinecardiologycardiovascular diseases
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-SMEINST-2-2016-2017
Régimen de financiación
SME-2 - SME instrument phase 2Coordinador
12559 Berlin
Alemania
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.